Parkinson’s & Movement Disorders Clinical Trials

Researchers at NYU Langone’s Fresco Institute for Parkinson’s and Movement Disorders conduct clinical trials to advance the understanding and treatment of Parkinson’s disease and movement disorders.

Sponsored Clinical Trials

The following sponsored clinical trials are currently enrolling participants.

Parkinson’s Disease

  • Exercise and Transcranial Magnetic Stimulation: Increasing Brain Plasticity in Parkinson’s Disease (A Feasibility Study)
  • Evaluation of the Personal KinetiGraph™ (PKG™) to Improve Insight into Parkinson’s Disease Status (APPRISE)
  • Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Assess the Efficacy, Safety, Pharmacokinetics, and Pharmacodynamics of GZ/SAR402671 in Patients with Early-Stage Parkinson’s Disease Carrying GBA Mutation or Other Prespecified Variant
  • Phase III, Multicenter, Randomized, Double-Blind, Double-Dummy, Active Controlled Study Comparing the Efficacy and Safety of Gastric Retentive, Controlled Release Accordion Pill™ Carbidopa/Levodopa (AP-CD/LD) to Immediate Release CD/LD in Fluctuating Parkinson’s Disease Patients
  • A Multicenter, Randomized, Double-Blind, Placebo-Controlled Study, with an Active-Treatment Dose-Blinded Period, to Evaluate the Safety, Pharmacokinetics, and Pharmacodynamics of BIIB054 in Subjects with Parkinson’s Disease
  • Effect of LY3154207 on Cognition in Mild-to-Moderate Parkinson’s Disease Dementia (PDD)
  • A randomized, placebo surgery controlled, double-blinded, multi-center, Phase 2 Clinical Trial, evaluating the efficacy and safety of VY-AADCO2 in Advanced Parkinson’s Disease with Motor Flucturations (short title: AADC in Advanced PD Trieal- ADAPT)

Dystonia

  • A Placebo-Controlled, Double Blind, Randomized, Cross Over Pilot Study of the Efficacy and Tolerability of Incobotulinum Toxin A (Xeomin®) As a Treatment for Focal Task-Specific Dystonia of the Musician’s Hand

Principal Investigator–Initiated Studies

The following principal investigator–initiated studies are seeking participants.

Parkinson’s Disease

  • Patient Research Registry for the Study of Non-Motor and Motor Manifestation of Parkinson’s Disease and Other Movement Disorders (PD-R)
  • Exploratory Study of Neurophysiologic Plastic Changes and Their Clinical Correlates After Multiple Sessions of Low-Frequency rTMS to Premotor Areas in Parkinson’s Patients: A Pilot Study
  • Visual Spatial Exploration and Art Therapy Intervention in Parkinson’s Disease
  • Remotely Supervised Transcranial Direct Current Stimulation (tDCS) for At-Home Treatment of Fatigue and Cognitive Slowing in Parkinson’s Disease: A Pilot Study
  • Exercise and Transcranial Magnetic Stimulation: Increasing Brain Plasticity in Parkinson’s Disease: An Exploratory and Feasibility Study
  • National Parkinson Foundation Patient Registry
  • Noninvasive TMS Neuromodulation for Enduring Balance and Locomotion Restoration in Parkinson’s Disease: A Feasibility and Pilot Study (Locom-TMS)

Other Movement Disorders

  • The New York Movement Disorder Study (NYMD)
  • Genetics of Complex Movement Disorders

Recently Completed Studies

The following studies were recently completed at NYU Langone.

  • A Phase 3, 12-Week, Double-Blind, Placebo- and Active-Controlled Efficacy and Safety Study of Preladenant in Subjects with Moderate to Severe Parkinson’s Disease (Phase 3, Protocol No. P04938) (closed 2013)
  • A Phase 3, 40-Week, Active-Controlled, Double-Blind, Double-Dummy Extension Study of Preladenant in Subjects with Moderate to Severe Parkinson’s Disease (Phase 3, Protocol No. P06153) (closed 2014)
  • A Multicenter, Double-Blind, Randomized, Parallel-Group, Placebo-Controlled Study to Assess the Clinical Effect of Droxidopa in the Treatment of Symptomatic Neurogenic Orthostatic Hypotension in Patients with Parkinson’s Disease (closed 2013)
  • Magnetic Stimulation for the Treatment of Motor and Mood Symptoms of Parkinson’s Disease (closed 2015)
  • Sleep and Learn with TMS in Parkinson’s Disease (closed 2014)
  • Efficacy and Safety of ADS-5102 (Amantadine HCL) Extended Release Capsule for the Treatment of Levodopa-Induced Dyskinesia in Parkinson’s Disease Patients (EASE LID Study) (closed 2016)
  • Istradefylline Study of Safety and Treatment Efficacy in Parkinsons (I-STEP)
  • Open-Label Safety Study of ADS-5102 (Amantadine HCL) Extended Release Capsules for the Treatment of Levodopa-Induced Dyskinesia (closed 2017)
  • A 12-week, Multicenter, Randomized, Parallel-Group Study to Assess the Safety and Tolerability by Positron Emission Tomography of AZD3241 in Subjects with Multiple System Atrophy
  • A Phase 3, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study with an Open-Label Phase to Determine the Efficacy and Safety of Tozadenant as Adjunctive Therapy in Levodopa-Treated Patients with Parkinson’s Disease (TOZ-PD)
  • Evaluation of an Interdisciplinary Medical Home Visit Program to Improve Outcomes for Advanced Parkinson’s Patients
  • Medication Beliefs of Patients with Parkinson’s Disease and their Caregivers
  • Post-Hospitalization Outcomes of Neurologic Inpatients Before and After Mandatory Follow-Up Appointment Scheduling

For more information about research at the Fresco Institute, contact our research team at 646-501-4367 or pdresearch@nyumc.org.